co.don AG is awarded the US-Patent: Process to produce cell transplants patented successfully
(Thomson Reuters ONE) -
co.don AG /
co.don AG is awarded the US-Patent: Process to produce cell transplants patented
successfully
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
Teltow. The German biotechnology enterprise co.don AG has announced yet another
great achievement. An important patent has been granted recently to the
Brandenburg enterprise by the American patent office "United States Patent and
Trademark Office". The refined method by co.don AG for growing three-dimensional
autologous cell transplants (ACT-3D) is now protected on the US market.
Application for a patent was filed back in 2001.
"Being awarded the patent gives us a leading position in technology and know-how
in North America," says Dr. Andreas Baltrusch, CEO of co.don AG. The US is one
of the largest health care markets worldwide. "The patent application,"
according to Dr. Baltrusch, "has been an important step towards selling co.don
AG products abroad in future."
The US-Patent, with the number 7 887 843 B2, protects the method of growing
transplants, the base for the co.don chondrosphere(® )product. These transplants
are used for the treatment of damages to the articular cartilage in knee, hip,
ankle, elbow and shoulder joints. For this treatment, healthy articular
cartilage cells are removed from the patient, then isolated in the laboratory
and by adding the patient's own blood serum, cultivated into a three-dimensional
cartilage cell transplant within a few weeks. With a minimally invasive
intervention, the autologous transplant is then implanted into the damaged
articular cartilage, a gentle method for the patient, which often makes the use
of prosthesis superfluous later on.
This patent-protected cell cultivation by co.don AG abstains completely from
using antibiotics, growing factors and fungistats (antifungal agents).
Furthermore, these products are made without any genetic modification and
without alien matrix despite its three-dimensionality.
About co.don(®) AG:
The enterprise being located in the Brandenburg town of Teltow was established
in 1993. Since 2001, the bio-pharmaceutical company is listed on the Frankfurt
stock exchange. By using tissue engineering - cultivation and growing of
autologous tissue cells, co.don(® )AG develops new products and therapy concepts
for the orthopaedic and neurosurgical market. The cell-based, biological
medicine (autologous cell transplants for articular cartilage as well as for
intervetebral discs) are made without the use of antibiotics, growing factors
and genetic engineering. The board of directors at co.don(®) AG consists of Dr.
Andreas Baltrusch (CEO) and Mrs. Vilma Siodla (COO).
Further information see also: www.codon.de
Press contact:
BrunoMedia Communication GmbH
Gerd J. Gauger
Bonner Straße 328
50968 Köln
Tel: 0221-348 038 10
Fax: 0221-348 038 41
Email: codon(at)brunomedia.de
--- End of Message ---
co.don AG
Warthestr. 21 Teltow Germany
WKN: 517360 ;ISIN: DE0005173603;Index:CDAX;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Niedersächsische Börse zu Hannover,
General Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press release (PDF):
http://hugin.info/132731/R/1496648/432362.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: co.don AG via Thomson Reuters ONE
[HUG#1496648]
Unternehmensinformation / Kurzprofil:
Datum: 14.03.2011 - 10:44 Uhr
Sprache: Deutsch
News-ID 52409
Anzahl Zeichen: 4492
contact information:
Town:
Teltow
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 213 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"co.don AG is awarded the US-Patent: Process to produce cell transplants patented successfully"
steht unter der journalistisch-redaktionellen Verantwortung von
co.don AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
